Treatment patterns and associated outcomes among patients with HER2+ metastatic breast cancer in the United States: an observational cohort study
Approximately one-quarter of the patients died or discontinued 1L therapy without receiving further treatment. Overall survival from the start of 1L was just over 3 years. This highlights a need for more effective therapies in earlier LoTs that prolong the time to progression and provide longer clinical benefits.
Authors
- Clara Lam (ORCID: https://orcid.org/0009-0000-8995-2697)
- Sandhya Mehta (ORCID: https://orcid.org/0000-0002-9326-1693)
- Brian R. Murphy (ORCID: https://orcid.org/0000-0002-3771-5283)
- Eleanor Faherty
- Beth Nordstrom (ORCID: https://orcid.org/0000-0003-1743-9610)
- Jenna Collins (ORCID: https://orcid.org/0000-0003-3781-8095)
- Della Varghese
Institutions
- Ithaka Harbors (US)
- Ider University (MN)
- AstraZeneca (Finland) (FI)
- Daiichi Sankyo (United States) (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1093/oncolo/oyae280
- Citations
- 4
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 4.18